Anzeige
Mehr »
Login
Mittwoch, 02.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
246 Leser
Artikel bewerten:
(1)

Steven Taylor, Arthritis Foundation CEO, Appointed to Advisory Council for the National Institute of Arthritis and Musculoskeletal and Skin Diseases

Finanznachrichten News

The announcement comes as the global arthritis community observes World Arthritis Day

ATLANTA, GA / ACCESSWIRE / October 10, 2024 / The Arthritis Foundation proudly announces the appointment of its President and CEO, Steven Taylor, to the Advisory Council of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This prestigious role underscores Taylor's leadership in public health and his unwavering commitment to improving the lives of the nearly 60 million adults and hundreds of thousands of kids living with arthritis in the U.S.

Comprised of leaders from the scientific and lay communities, the role of the NIAMS Advisory Council is to advise the organization about its research portfolio and provide a secondary review of grant applications that have earned a favorable recommendation from a scientific peer group. The Council's work supports the NIAMS strategic plan which seeks to develop patient-centered, personalized ways to improve outcomes. Taylor's selection to the NIAMS Advisory Council is a testament to his leadership in the voluntary health space and his dedication to advancing arthritis research and patient care.

"Steven's appointment to the NIAMS Advisory Council is a significant achievement not only for him, but also for the Arthritis Foundation and the millions we serve," said Matt Mooney, Board Chair of the Arthritis Foundation. "Given that there's no FDA-approved treatment for osteoarthritis - the most common type - and rheumatoid arthritis treatments don't work for one in five patients, the critical need for more scientific research is clear."

Taylor, who has served as President and CEO of the Arthritis Foundation since 2022, has more than three decades of experience in patient advocacy and nonprofit leadership. Prior to joining the Foundation, he led the Sjogren's Foundation, where he spearheaded groundbreaking clinical guidelines for disease management. Taylor has also held leadership roles with the American Heart Association and the American Cancer Society.

"I'm honored to join the NIAMS Advisory Council and to represent the patient voice at such an important time," said Taylor. "As we mark World Arthritis Day on October 12, I am also proud of the thought leadership and advocacy of Arthritis Foundation staff in communities across the country. The Arthritis Foundation remains committed to being the number one resource available to patients as we support those working diligently to find a cure."

For more information, visit arthritis.org.

About the Arthritis Foundation

The Arthritis Foundation is fighting for all people who live with arthritis. As Champions of Yes, the Arthritis Foundation has a mission to turn the obstacles arthritis causes into opportunities. The Arthritis Foundation not only champions life-changing solutions and medical advancements, but it also provides ways for people to connect, break down barriers in health care and join the fight to conquer arthritis - uniting hearts, minds and resources to change the future of arthritis. To join the fight to conquer arthritis, visit arthritis.org.

CONTACT:

Jill Konopka
jkonopka@mower.com
959.888.1554

SOURCE: Arthritis Foundation



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.